ErbB-4 is a member of the ErbB receptor tyrosine kinase family, which also includes ErbB-1 (EGF receptor), ErbB-2 and ErbB-3 (Carpenter, 2003). In the cases of ErbB-1 and ErbB-4, ligand binding ...
A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial ...
ErbB-2 overexpression in breast tumors is associated with poor survival. Expression of Notch-1 and its ligand, Jagged-1, is associated with the poorest survival, including ErbB-2-positive tumors.
PHILADELPHIA – Combination of the KRAS inhibitor sotorasib (Lumakras) with afatinib, a pan-ErbB tyrosine kinase inhibitor, was feasible in treating non-small cell lung cancer (NSCLC) patients with ...
ErbB-2 (human epidermal growth factor receptor 2) overexpression may be predictive of relative resistance and/or sensitivity to specific chemotherapeutic agents. Results from a previous study from the ...
Cholangiocarcinoma is a rare but highly malignant primary hepatobiliary cancer with a high rate of mortality. Early diagnosis is difficult and current therapies are ineffective for the advanced ...
A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 ...
A team at the Medical University of Vienna has uncovered a promising new approach for tackling one of the most stubborn forms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results